ישראל -
עברית -
Ministry of Health
אלטרנטיב פלוס -מי פנים מרעננים ללא אלכוהול
מיסנס קוסמטיקס בעמ - ניקוי הפנים
ישראל -
עברית -
Ministry of Health
טייקרב
novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.
ישראל -
עברית -
Ministry of Health
טאלץ 80 מג
eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab
ישראל -
עברית -
Ministry of Health
אנראביק % 10 וטרינרי
abic veterinary products ltd - enrofloxacin - תמיסה - enrofloxacin 100 mg/ml
ישראל -
עברית -
Ministry of Health
אס.סי. פי. 47 וטרינרי
abic veterinary products ltd - sulfachlorpyrazine sodium monohydrate - אבקה להכנת תמיסה - sulfachlorpyrazine sodium monohydrate 47 %w/w
ישראל -
עברית -
Ministry of Health
אס.סי.פי. גל וטרינרי
biovac ltd., israel - sulfachlorpyrazine as sodium monohydrate - אבקה להכנת תמיסה - sulfachlorpyrazine as sodium monohydrate 30 %
ישראל -
עברית -
Ministry of Health
בוטומידור 10 מג מל וטרינרי
vetmarket ltd, israel - butorphanol as tartrate - תמיסה להזרקה - butorphanol as tartrate 10 mg/ml
ישראל -
עברית -
Ministry of Health
סולפמתופרים פרמיקס וטרינרי
abic veterinary products ltd - sulphadiazine; trimethoprim - אבקה - sulphadiazine 250 mg/g; trimethoprim 50 mg/g
ישראל -
עברית -
Ministry of Health
טייסברי
medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.